ResMed RMD shares rallied 4.2% in the last trading session to close at $218.4. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

Selling the software business to Frazier Healthcare Partners will allow the respiratory device maker to shift more resources to faster-growing parts of its portfolio.

Resmed’s decision to sell MatrixCare to PE firm Frazier Healthcare Partners comes less than a decade after its $750m acquisition of the software business.

ResMed Inc. RMD agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm ...

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its ...

ResMed (RMD) stock faces a downgrade at RBC Capital Markets due to potential challenges the company is set to face in FY27.

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...

Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock ...